FDA halts clinical trials on HIV drug candidate of GlaxoSmithKline
An HIV drug candidate licensed by GlaxoSmithKline has received a clinical hold, stopping further clinical trials on the compound. The U.S. Food and Drug Administration's action could jeopardize $390 million in milestone payments to GSK partner Idenix Pharmaceuticals